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Abstract 
Multiple myeloma (MM) is a haematological malignancy characterized by 
terminally differentiated plasma cells and their accumulation in the bone 
marrow (BM). Despite significant advances in therapeutic strategies it 
currently remains incurable. The interactions between the BM 
microenvironment and malignant plasma cells have been pivotal to 
understanding this disease. Previous reports have shown that patients with a 
haematological malignancy sustain “damage” to their BM, but how much of 
this is due to the disease and/or the treatment is currently unknown. 
Furthermore MM plasma cells have been documented to harness the BM 
microenvironment to their advantage, improving their growth and survival. 
However, little is known about the functionality of BM mesenchymal stem cells 
(MSC) in patients with MM disease which form an essential compartment of 
the BM microenvironment. It was hypothesised that MSC altruistically protect 
MM cells from therapy and consequently become phenotypically and 
genetically compromised. 
To facilitate the study of the effects of chemotherapeutic agents and MM cells 
on MSC, a non-contact co-culture model was developed that allowed the 
investigation of functional and genetic damage. In line with previous studies, 
the MM cell line, U266B1 were found to be protected from drug-induced cell 
death when in co-culture with the stromal cell line HS5. However, the 
promoting effects of the BM appear to be at the detriment to their own survival. 
HS5 cells were found to have lower viability, altered morphology and disrupted 
differentiation when in a non-contact co-culture with U266B1 cells.  
Results from this study have revealed that interactions of MSC with MM cells 
lead to an altruistic protection of MM cells by the BM. This work demonstrates 
that U266B1 cells have an improved viability following exposure to 
chemotherapy when in a non-contact co-culture with MSC/HS5. Furthermore, 
genotoxic assays also revealed that HS5/MSC interactions with U266B1 cells 
protect U266B1 from the genotoxic effects of melphalan in co-culture, whilst 
for the first time HS5 morphology was shown to be severely altered following 
exposure to chemotherapy and when in co-culture with U266B1 cells. 
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This work has demonstrated, for the first time, the cytotoxic effects of novel 
agents bortezomib and carfilzomib on HS5 cells when in co-culture with 
U266B1 cells.  Results from this study also demonstrate that melphalan 
severely effects the ability of HS5 cells to differentiate in an osteogenic lineage 
with a further deficiency in differentiation when in co-culture with U266B1. 
Adipogenic differentiation of HS5 was unable to take place when in co-culture 
with MM cells and was again further impaired by chemotherapy. This is the 
first study to reveal that primary MSC secrete significantly high concentrations 
of IL-6 compared to the stromal cell line HS5. A further increase in expression 
of IL-6 was also shown when in co-culture with U266B1 cells. 
Increased multi-nucleation was also identified in both HS5 and U266B1 cells 
when exposed to either thalidomide, lenalidomide and bortezomib with 
abnormalities providing possible explanations for the therapy related 
malignancies and neurotoxicity that is seen in some patients. Genotoxicity to 
the MSC/HS5 compartment of the co-culture measured by the micronucleus 
assay was also found to be reduced suggesting that the BM is protected from 
the DNA damaging effects of some agents when in co-culture with MM cells. 
Combined work on the functionality and genotoxicity of the interactions 
between the BM and MM reveal a tropism of MSC and HS5 towards the MM 
cell line U266B1. With this research being conducted in a non-contact co-
culture, it has indicated that cell-cell contact is not essential to provide 
protection of both the BM and MM cells against chemotherapy. This research 
provides further understanding of the MSC and MM interactions’ impact on the 
functionality of the BM and their protection from genotoxic damage. 
Elucidating the consequence of cytotoxic and genotoxic damage to MSC via 
chemotherapy treatment and/or through haematological disease may allow for 
the development of effective therapies and improve the quality of life for 
patients with MM. 
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